Skip to main content
. 2022 May 10;13:2543. doi: 10.1038/s41467-022-30105-0

Fig. 6. Treatment with a clinically applicable FAK inhibitor blocks EZH2-induced breast cancer bone metastasis.

Fig. 6

a Representative bioluminescence images of and quantification of the fold change in BLI intensity in the right leg region in three subgroups of mice (n = 5 in each group) intratibially injected with MDA-MB-231 cells and given treatment with a vehicle, GSK126 (100 mg/kg/day, i.p. injection), or the FAKi VS-6063 (50 mg/kg, twice a day, oral gavage) beginning on day 18 of injection. The BLI signal was normalized according to the signal on the first day after injection. Data are presented as means ± S.D. t-test (two-sided). b, c Representative pictures of IHC staining and quantification of pS465/467-Smad2 and PTHLP expression in the bone metastasis samples obtained from the three subgroups of mice in a. Data are presented as means ± S.E.M. t-test (two-sided). n = 4 bone metastasis slices in vehicle subgroup; n = 5 bone metastasis slices in GSK126 subgroup; n = 3 bone metastasis slices in FAKi subgroup. Scale bars, 50 μm. d The Pearson r correlation for EZH2 RNA expression and bone metastasis-free survival years (bmfs Yr) in breast cancer patients (GSE2603 dataset). e The Pearson r correlation for EZH2 and PTHLH RNA mRNA expression in bone metastasis samples obtained from breast cancer patients (GSE14020 dataset). All P-values are indicated in the figures.